新西兰与澳大利亚在获取新药方面的比较。

Access to new medicines in New Zealand compared to Australia.

作者信息

Wonder Michael, Milne Richard

出版信息

N Z Med J. 2011 Nov 25;124(1346):12-28.

PMID:22143849

Abstract

AIM

To compare access to new prescription-only medicines in New Zealand (NZ) with that in Australia.

METHOD

The range of new prescription medicines and the timing of their regulatory approval and reimbursement in NZ and Australia in the period 2000 to 2009 were compared.

RESULTS

136 new prescription medicines were first listed in the Australian Schedule of Pharmaceutical Benefits in the study period and 59 (43%) of these were listed in the NZ Pharmaceutical Schedule. Listing of these 59 medicines for reimbursement occurred later in NZ (mean difference=32.7 months; 95% CI 24.2 to 41.2 months; p<0.0001) due largely to a longer time from registration to listing (mean difference=23.7 months; 95% CI 14.9 to 32.4 months; p<0.0001). The remaining 77 medicines that are reimbursed in Australia but not in NZ cover a wide range of therapeutic areas, including some diseases for which there are no reimbursed medicines in NZ. Four new medicines were listed in NZ but not Australia.

CONCLUSION

In the last decade, public access to new medicines in NZ has been more limited and delayed compared to Australia.

摘要

目的

比较新西兰（NZ）和澳大利亚获取新型处方药的情况。

方法

比较了2000年至2009年期间新西兰和澳大利亚新型处方药的范围及其监管批准和报销的时间。

结果

在研究期间，136种新型处方药首次列入澳大利亚药品福利清单，其中59种（43%）列入了新西兰药品清单。这59种药品在新西兰的报销列期较晚（平均差异=32.7个月；95%可信区间24.2至41.2个月；p<0.0001），主要是因为从注册到列期的时间更长（平均差异=23.7个月；95%可信区间14.9至32.4个月；p<0.0001）。其余77种在澳大利亚可报销但在新西兰不可报销的药品涵盖了广泛的治疗领域，包括一些在新西兰没有可报销药品的疾病。有4种新药在新西兰列入清单但未在澳大利亚列入。